Company Overview and News


Add RAP
to your dashboard

Headline News

ResApp Health director provides share support through on-market buying

2017-10-06 proactiveinvestors.com.au
ResApp Health Ltd's (ASX:RAP) executive director, Brian Leedman, has provided support for the company's valuation through the purchase of 876,000 shares on-market this week for a consideration of $64,500.

ResApp Health's shares are being snapped up

2017-09-22 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) has received a notice of initial substantial shareholder from Ian Francis Reynolds, who now holds circa 37 million shares for a 5.6% stake.

Resapp Health to restart respiratory app study after enhancing its technology

2017-09-14 proactiveinvestors.com.au
Resapp Health Ltd (ASX:RAP) is planning to restart the U.S. paediatric clinical study of its “ResAppDx” app to detect respiratory diseases, this U.S. winter.

ResApp Health director buys 1,000,000 shares on-market

2017-08-10 proactiveinvestors.com.au
ResApp Health Ltd's (ASX:RAP) non-executive director, Chris Ntoumenopoulos, has thrown his support behind the company by purchasing one million shares on-market for a consideration of $72,821.92.

ResApp Health is the ASX Volume Leader as investor call breathes in new life

2017-08-10 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) shares have soared in afternoon trading, following a massive sell-off yesterday, after the results preliminary top-line results from the SMARTCOUGH-C Study.

ResApp crashes on study results

2017-08-09 businessnews.com.au
Shares in medical tech company ResApp Health plummeted 77 per cent today on disappointing results of a clinical study on its ResAppDx technology.

ResApp, Atlas Iron and ZipTel top ASX Volume Leaders, but head in different directions

2017-08-09 proactiveinvestors.com.au
There has been some frantic trading in the small caps by mid-session, with high volume not indicating a valuation direction.

ResApp Health the leading ASX % Faller in morning trade on big volume

2017-08-09 proactiveinvestors.com.au
ResApp Health Ltd's (ASX:RAP) shares have plunged 76% to $0.074 in the first 90 minutes of trade following the company reporting preliminary top-line results from the SMARTCOUGH-C Study.

ResApp Health's shares in pre-open pending partnership update

2017-05-08 proactiveinvestors.com.au
ResApp Health (ASX:RAP) has been granted a trading halt by the ASX, pending an update on the company’s partnership with a humanitarian organisation.

ResApp Health expands study of app to diagnose pneumonia

2017-04-19 proactiveinvestors.com.au
ResApp Health (ASX:RAP) is expanding its study to evaluate the efficacy of the ResAppDx app for the diagnosis of childhood pneumonia and other respiratory conditions.

ResApp Health extends partnership with Massachusetts General Hospital

2017-01-10 proactiveinvestors.com.au
SMARTCOUGH-C is a study that is evaluating the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions from cough sounds.

ResApp Health begins U.S. trial of app to diagnose respiratory diseases

2016-12-11 proactiveinvestors.com.au
ResApp’s smartphone app works by using algorithms to analyse the sound of a patient’s cough and provide a diagnosis. The multi-site clinical study in the U.S. aims to recruit up to 1,111 patients between the ages of 29 weeks and 12 years. The primary endpoint of the study is the diagnosis of pneumonia compared to radiologic and clinical diagnosis. The secondary endpoint is the diagnosis of other common childhood respiratory diseases such as upper respiratory tract infection, croup, bronchiolitis and asthma compared with a clinical diagnosis.

ResApp Health Ltd to begin diagnosis app study in the U.S.

2016-11-16 proactiveinvestors.com.au
SMARTCOUGH-C is a study that will evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions from cough sounds. ResApp has developed a smartphone app that works by using algorithms to analyse the sound of a patient’s cough and provide a diagnosis. The primary endpoint of the U.S. based study will be the diagnosis of pneumonia with the secondary endpoint being diagnosis of other common childhood respiratory diseases.

Smartphone app claiming to diagnose asthma and pneumonia trialled in WA

2016-11-15 smh.com.au
Diagnosing asthma and pneumonia could become as easy as coughing into a phone with Perth researchers trialling a potentially revolutionary app.

ResApp Health Ltd app to diagnose respiratory diseases from cough sounds

2016-11-11 proactiveinvestors.com.au
SMARTCOUGH-C is a study that will evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood pneumonia and other respiratory conditions from cough sounds. ResApp’s smartphone app works by using algorithms to analyse the sound of a patient’s cough and providing a diagnosis. The primary endpoint for the new study will be the diagnosis of pneumonia with the secondary endpoints being diagnosis of other common childhood respiratory diseases.

ResApp Health Ltd awarded best venture capital raising of 2016

2016-08-19 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) develops smartphone medical applications for the diagnosis and management of respiratory disease.

ResApp looking for US study hospitals

2016-06-30 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

ResApp looking for US study hospitals

2016-06-30 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

Shark Mitigation hits top Techboard spot

2016-06-27 businessnews.com.au
Shark Mitigation Systems has climbed to the top of Techboard’s latest trending startup ranking, having spent the previous three fortnights at number two.

ResApp Health Ltd to reveal clinical results

2016-06-20 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) develops smartphone medical applications for the diagnosis and management of respiratory disease.

ResApp Health Ltd app detects respiratory disease through a smart phone

2016-06-16 proactiveinvestors.com.au
ResApp Health Ltd (ASX:RAP) develops smartphone medical applications for the diagnosis and management of respiratory disease.

Investor Presentation

2016-05-03 asx.com.au

Appendix 4C - quarterly

2016-04-29 asx.com.au

Cleansing Prospectus

2016-04-28 asx.com.au